NRSN Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Neurosense

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

a month ago - By: Neurosense

NeuroSense to Host Investor Webinar on December 8, 2025

2 months ago - By: Neurosense

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

3 months ago - By: Benzinga - Mentions: XRTX RNA KZIA APM ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

3 months ago - By: Neurosense

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

a year ago - By: BusinessInsider

NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024

3 months ago - By: Neurosense

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

4 months ago - By: Neurosense

NeuroSense Provides Business Update and Progress for the First Half of 2025

4 months ago - By: Neurosense

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

7 months ago - By: Yahoo Finance - Mentions: GLP CRSP VRTX DHI ...

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

7 months ago - By: Benzinga

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

7 months ago - By: Yahoo Finance - Mentions: COIN MS HLT DB ...

Target downgraded, Wayfair upgraded: Wall Street's top analyst calls

7 months ago - By: Neurosense

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

7 months ago - By: Neurosense

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

8 months ago - By: Neurosense

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

8 months ago - By: Neurosense

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

8 months ago - By: Neurosense

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

9 months ago - By: Market News Alerts

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

9 months ago - By: PESG Research

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

a year ago - By: Neurosense

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

a year ago - By: Neurosense

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

a year ago - By: Neurosense

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

a year ago - By: Neurosense

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

a year ago - By: Neurosense

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

a year ago - By: Neurosense

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

a year ago - By: Neurosense

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

a year ago - By: Neurosense

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

a year ago - By: Neurosense

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

a year ago - By: Neurosense

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

a year ago - By: Neurosense

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

a year ago - By: Neurosense

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

a year ago - By: Neurosense

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

a year ago - By: Neurosense

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NEUROSENSE THERAPEUTICS LTD (NRSN) Stock News

NRSN Latest News, Press Relases and Analysis